首頁 > 市場調查報告書 > 醫療設備

生技設備基因治療學和RNAi

市場調查報告書

商品編碼

1497722

全球 DNA 微陣列市場、市場規模和佔有率分析：依類型、應用和最終用戶 - 需求預測（~2030 年）

DNA Microarray Market Size and Share Analysis by Type, Application, End User - Global Industry Demand Forecast to 2030

出版日期: 2024年05月07日 | 出版商:

Prescient & Strategic Intelligence | 英文 270 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

市場概況

2023年，全球DNA微陣列產業營收為19.821億美元，預估至2030年將達39.308億美元，預測期間內複合年增長率為10.5%。

市場的發展可以透過檢測過程和 IT 領域對該技術的認識和使用不斷增加以及所用軟體的發展來解釋。DNA 微陣列適用於多種應用，從農業生物技術到疾病診斷和監測、蛋白質表現和蛋白質體學。

DNA 微陣列在專門設計的診斷和預後、標靶治療和許多其他疾病途徑方面不斷取得進展。首先，傳統的治療方法無法提供準確的診斷或治療。因此，個人化醫療正在被考慮。

癌症和免疫疾病是最具威脅的疾病，對基因組的完整瞭解可以對預後和治療產生重大影響。因此，隨著越來越多的人支持個人化醫療，我們看到該行業正在擴張。

DNA 微陣列是基因組作圖和定序過程中常見的重要組成部分。然而，儘管這是最近的考慮，這些微陣列研究在傳染病的診斷和檢測、疾病的遺傳基礎、癌症診斷、新藥研究、藥物基因組學等方面的應用正在增加。

重要考慮因素

寡核甘酸DNA微陣列類別預計將佔據最大佔有率，為70%，並且由於其成本效率和精確的基因表現監測能力而保持其主導地位。

寡核甘酸 DNA 微陣列因其篩選雜交特異性的潛力而被認為是單核甘酸多態性 (SNP) 研究的重要技術。

由於該技術在研究多個物種的基因表現的重要應用，預計 cDNA 微陣列片段將創下最高的複合年增長率。

到2023年，製藥和生物技術產業將佔最大佔有率，超過40%，並且隨著DNA微陣列在藥物發現和研究中的接受度不斷提高，該類別也有望保持其主導地位。

旨在發現新藥物分子的研究和開發正在支持該類別的產業成長。

DNA 微陣列在癌症研究中變得越來越重要，它對具有診斷許多人類癌症潛力的分子標記進行分類。

在臨床診斷中接受 DNA 微陣列技術的推動下，醫院和診斷中心預計將出現最快的成長。

先進的實驗室正在利用 DNA 微陣列在基於生物晶片的單一檢測中檢測大量多態性。

2023年，北美地區預計將佔據約40%的較大佔有率，並以較高的複合年增長率成長。

這項發展的主要動力是大型工業公司投資於技術增強的 DNA 微陣列。

在這片大陸上，難以診斷和治療的疾病數量正在迅速增加，促使對微陣列的需求不斷增加。

由於良好的醫療基礎設施、啟動完整糖尿病治療的政府支持系統以及慢性病的快速增加，加拿大市場正在迅速成長。

醫療產業（尤其是生物技術）的收入動態很大程度上受到北美創新投資的影響。

本報告研究和分析了全球 DNA 微陣列市場，提供市場動態、依地區和細分市場劃分的市場收入以及競爭格局等資訊。

The development of this market can be explained by the increase in awareness and use of this technology in the detection process and IT world and, the evolution of software for it. DNA microarray has several applications ranging from agricultural biotechnology to disease diagnosis & monitoring, to protein expression & proteomics, and so on.

DNA microarrays are an ongoing advancement in the specially designed pathway for the very purpose of - diagnosis and prognosis, targeted therapies, and many other conditions. First of all, the treatment methods of the diseases through the traditional way they cannot make the precise diagnosis and treat the disease. Because of that, personalized medicine has come to be considered.

These diseases comprising of cancer and immune disorders are the most threatening of the bunch which bring great implications on each person's prognosis and treatment by considering the acquisition of full genome understanding. Thus, along with this rise in the number of individuals who are in favor of tailored medicine, we can see the expansion of the industry.

The DNA microarray is a crucial component that is everywhere in genome mapping and sequencing processes. However, despite of this quite recent observation, the application of these microarray studies rose in diagnostics and detection of diseases of infectious origin, genetic basis of diseases, cancer diagnostics, new drugs research, pharmacogenomics, etc.

Key Insights

The oligonucleotide DNA microarray category held the largest share, 70%, and is estimated to uphold supremacy because of cost-efficiency and accurate gene expression monitoring abilities.

It has the potential to screen hybridization specificity and therefore is regarded as a key technique for researching single nucleotide polymorphisms (SNPs).

The cDNA microarray segment is projected to record the highest CAGR, given the vital applications of this technology in studying gene expression across several species.

In 2023, the pharmaceutical & biotechnology industry held the largest share, of more than 40%, and the category is also projected to remain dominant because of augmented acceptance of DNA microarrays in drug discovery and research.

Development in research activities for finding new drug molecules supports industry growth in this category.

DNA microarrays are attaining significance in cancer research, classifying molecular markers with diagnostic potential for numerous human cancers.

Hospitals & diagnostic centers will witness the fastest development, propelled by the acceptance of DNA microarray tech in clinical diagnostics.

Advanced laboratories utilize DNA microarrays for detecting numerous polymorphisms in a single assay using biochips.

In 2023, the North American region had a significant share, around 40%, and is forecasted to advance at a strong CAGR.

Major reasons propelling this development include the existence of key industry players investing in technically enhanced DNA microarray items.

The continent witnessed a surge in difficult-to-diagnose and treat diseases, leading to augmented demand for microarrays.

Canada's market is growing rapidly with the boom of superior healthcare infrastructure, government support systems initiating perfect diabetes, and the surge of chronic diseases.

Revenue dynamics in the healthcare sector, in particular biotechnology, are largely influenced by innovative investments in North America.

Chapter 1. Research Scope

1.1. Research Objectives
1.2. Market Definition
1.3. Analysis Period
1.4. Market Size Breakdown by Segments
- 1.4.1. Market size breakdown, by type
- 1.4.2. Market size breakdown, by application
- 1.4.3. Market size breakdown, by end user
- 1.4.4. Market size breakdown, by region
- 1.4.5. Market size breakdown, by country
1.5. Market Data Reporting Unit
- 1.5.1. Value
1.6. Key Stakeholders

Chapter 2. Research Methodology

2.1. Secondary Research
- 2.1.1. Paid
- 2.1.2. Unpaid
- 2.1.3. P&S Intelligence database
2.2. Primary Research
2.3. Market Size Estimation
2.4. Data Triangulation
2.5. Currency Conversion Rates
2.6. Assumptions for the Study
2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Voice of Industry Experts/KOLs

Chapter 5. Market Indicators

Chapter 6. Industry Outlook

6.1. Market Dynamics
- 6.1.1. Trends
- 6.1.2. Drivers
- 6.1.3. Restraints/challenges
- 6.1.4. Impact analysis of drivers/restraints
6.2. Impact of COVID-19
6.3. Porter's Five Forces Analysis
- 6.3.1. Bargaining power of buyers
- 6.3.2. Bargaining power of suppliers
- 6.3.3. Threat of new entrants
- 6.3.4. Intensity of rivalry
- 6.3.5. Threat of substitutes
6.4. Technology Analysis
6.5. Regulatory Framework

Chapter 7. Competitive Landscape

7.1. List of Market Players and their Offerings
7.2. Competitive Benchmarking of Key Players
7.3. Product Benchmarking of Key Players
7.4. Recent Strategic Developments

Chapter 8. Global Market

8.1. Overview
8.2. Market Revenue, by Type (2017-2030)
8.3. Market Revenue, by Application (2017-2030)
8.4. Market Revenue, by End User (2017-2030)
8.5. Market Revenue, by Region (2017-2030)

Chapter 9. North America Market

9.1. Overview
9.2. Market Revenue, by Type (2017-2030)
9.3. Market Revenue, by Application (2017-2030)
9.4. Market Revenue, by End User (2017-2030)
9.5. Market Revenue, by Country (2017-2030)

Chapter 10. Europe Market

10.1. Overview
10.2. Market Revenue, by Type (2017-2030)
10.3. Market Revenue, by Application (2017-2030)
10.4. Market Revenue, by End User (2017-2030)
10.5. Market Revenue, by Country (2017-2030)

Chapter 11. APAC Market

11.1. Overview
11.2. Market Revenue, by Type (2017-2030)
11.3. Market Revenue, by Application (2017-2030)
11.4. Market Revenue, by End User (2017-2030)
11.5. Market Revenue, by Country (2017-2030)

Chapter 12. LATAM Market

12.1. Overview
12.2. Market Revenue, by Type (2017-2030)
12.3. Market Revenue, by Application (2017-2030)
12.4. Market Revenue, by End User (2017-2030)
12.5. Market Revenue, by Country (2017-2030)

Chapter 13. MEA Market

13.1. Overview
13.2. Market Revenue, by Type (2017-2030)
13.3. Market Revenue, by Application (2017-2030)
13.4. Market Revenue, by End User (2017-2030)
13.5. Market Revenue, by Country (2017-2030)

Chapter 14. U.S. Market

14.1. Overview
14.2. Market Revenue, by Type (2017-2030)
14.3. Market Revenue, by Application (2017-2030)
14.4. Market Revenue, by End User (2017-2030)

Chapter 15. Canada Market

15.1. Overview
15.2. Market Revenue, by Type (2017-2030)
15.3. Market Revenue, by Application (2017-2030)
15.4. Market Revenue, by End User (2017-2030)

Chapter 16. Germany Market

16.1. Overview
16.2. Market Revenue, by Type (2017-2030)
16.3. Market Revenue, by Application (2017-2030)
16.4. Market Revenue, by End User (2017-2030)

Chapter 17. France Market

17.1. Overview
17.2. Market Revenue, by Type (2017-2030)
17.3. Market Revenue, by Application (2017-2030)
17.4. Market Revenue, by End User (2017-2030)

Chapter 18. U.K. Market

18.1. Overview
18.2. Market Revenue, by Type (2017-2030)
18.3. Market Revenue, by Application (2017-2030)
18.4. Market Revenue, by End User (2017-2030)

Chapter 19. Italy Market

19.1. Overview
19.2. Market Revenue, by Type (2017-2030)
19.3. Market Revenue, by Application (2017-2030)
19.4. Market Revenue, by End User (2017-2030)

Chapter 20. Spain Market

20.1. Overview
20.2. Market Revenue, by Type (2017-2030)
20.3. Market Revenue, by Application (2017-2030)
20.4. Market Revenue, by End User (2017-2030)

Chapter 21. China Market

21.1. Overview
21.2. Market Revenue, by Type (2017-2030)
21.3. Market Revenue, by Application (2017-2030)
21.4. Market Revenue, by End User (2017-2030)

Chapter 22. Japan Market

22.1. Overview
22.2. Market Revenue, by Type (2017-2030)
22.3. Market Revenue, by Application (2017-2030)
22.4. Market Revenue, by End User (2017-2030)

Chapter 23. India Market

23.1. Overview
23.2. Market Revenue, by Type (2017-2030)
23.3. Market Revenue, by Application (2017-2030)
23.4. Market Revenue, by End User (2017-2030)

Chapter 24. South Korea Market

24.1. Overview
24.2. Market Revenue, by Type (2017-2030)
24.3. Market Revenue, by Application (2017-2030)
24.4. Market Revenue, by End User (2017-2030)

Chapter 25. Australia Market

25.1. Overview
25.2. Market Revenue, by Type (2017-2030)
25.3. Market Revenue, by Application (2017-2030)
25.4. Market Revenue, by End User (2017-2030)

Chapter 26. Brazil Market

26.1. Overview
26.2. Market Revenue, by Type (2017-2030)
26.3. Market Revenue, by Application (2017-2030)
26.4. Market Revenue, by End User (2017-2030)

Chapter 27. Mexico Market

27.1. Overview
27.2. Market Revenue, by Type (2017-2030)
27.3. Market Revenue, by Application (2017-2030)
27.4. Market Revenue, by End User (2017-2030)

Chapter 28. Saudi Arabia Market

28.1. Overview
28.2. Market Revenue, by Type (2017-2030)
28.3. Market Revenue, by Application (2017-2030)
28.4. Market Revenue, by End User (2017-2030)

Chapter 29. South Africa Market

29.1. Overview
29.2. Market Revenue, by Type (2017-2030)
29.3. Market Revenue, by Application (2017-2030)
29.4. Market Revenue, by End User (2017-2030)

Chapter 30. U.A.E. Market

30.1. Overview
30.2. Market Revenue, by Type (2017-2030)
30.3. Market Revenue, by Application (2017-2030)
30.4. Market Revenue, by End User (2017-2030)

Chapter 31. Company Profiles

31.1. Thermo Fisher Scientific Inc.
- 31.1.1. Business overview
- 31.1.2. Product and service offerings
- 31.1.3. Key financial summary
31.2. Agilent Technologies Inc.
- 31.2.1. Business overview
- 31.2.2. Product and service offerings
- 31.2.3. Key financial summary
31.3. Illumina Inc.
- 31.3.1. Business overview
- 31.3.2. Product and service offerings
- 31.3.3. Key financial summary
31.4. F. Hoffmann-La Roche Ltd.
- 31.4.1. Business overview
- 31.4.2. Product and service offerings
- 31.4.3. Key financial summary
31.5. QIAGEN N.V.
- 31.5.1. Business overview
- 31.5.2. Product and service offerings
- 31.5.3. Key financial summary
31.6. Merck KGaA
- 31.6.1. Business overview
- 31.6.2. Product and service offerings
- 31.6.3. Key financial summary
31.7. PerkinElmer Inc.
- 31.7.1. Business overview
- 31.7.2. Product and service offerings
- 31.7.3. Key financial summary
31.8. Applied Microarrays LLC
- 31.8.1. Business overview
- 31.8.2. Product and service offerings
- 31.8.3. Key financial summary
31.9. Savyon Diagnostics
- 31.9.1. Business overview
- 31.9.2. Product and service offerings
- 31.9.3. Key financial summary